Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
DEA final rule places four synthetic cannabinoids (4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, MMB-FUBICA) into Schedule I, making them illegal to possess, manufacture, or distribute.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Critical. All pharmacies, especially independent, retail chains, compounding, and long-term-care pharmacies should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective immediately upon publication (May 1, 2026); no grace period.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Four synthetic cannabinoids are now Schedule I controlled substances; any handling without DEA registration is illegal.
Who it affects
All pharmacies, especially independent, retail chains, compounding, and long-term-care pharmacies
What you must do
Immediately cease any possession, dispensing, or distribution of these substances; update inventory and disposal procedures.
Deadline
Effective immediately upon publication (May 1, 2026); no grace period.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- TX HB 7: Relating to prohibitions on the manufacture and provision of abortion-inducing drugs, including the jurisdiction of and effect of certain judgments by courts within and outside this state with respect to the manufacture and provision of those drugs, and to protections from certain counteractions under the laws of other states and jurisdictions; authorizing qui tam actions.
- US-CONGRESS HR7895: PBM Kickback Prohibition Act
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications